Company intelligence / Profile preview

Keyan Biotechnology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Keyan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of innovative gene therapies. The company leverages its proprietary adeno-associated virus (AAV) platform to create treatments for high-unmet-need conditions, primarily focusing on ophthalmology and central nervous system (CNS) disorders. Its lead programs target neovascular age-related macular degeneration and other retinal diseases through long-lasting, single-injection gene therapies. Keyan Bio is backed by prominent life science investors and aims to provide transformative solutions for patients with chronic degenerative diseases.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyBiologicAdeno-associated virus vector
Industry: Biotech

Beyond the preview

Go deeper on Keyan Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keyan Biotechnology.

Explore the full profile